Short and Long-Term Prognostic Significance of Galectin-3 in Patients with ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
Angiology · 2023-10 · 74 (9) · 889-896
DOI: 10.1177/00033197221149846 ↗Kurz gefasst
Fachartikel in der Zeitschrift Angiology, online erschienen am 03.01.2023. Verfasst von Uğur Köktürk und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Mehmet Akif Ersoy Thoracic and Cardiovascular Surgery Center, Training and Research Hospital, Istanbul, Turkey. Hauptthemen laut MEDLINE: ST Elevation Myocardial Infarction, Percutaneous Coronary Intervention, Heart Failure. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 26 Literaturangaben.
Abstract (Originalsprache)
This study evaluated the short and long-term prognostic value of galectin-3 in patients with ST-segment elevation myocardial infarction (STEMI) who underwent primary percutaneous coronary intervention (PCI). Patients (n = 143) were admitted with STEMI and followed up for 2 years. The study population was divided into high and low galectin-3 groups based on the admission median value of serum galectin-3. Primary clinical outcomes consisted of cardiovascular (CV) mortality, non-fatal reinfarction, stroke, and target vessel revascularization (TVR). CV events were recorded in hospital and at 1 and 2 years. The primary clinical outcomes (in-hospital, 1 year and 2 year) were significantly higher in the high galectin-3 group. ( P = .008, P = .004, P = .002, respectively). High galectin-3 levels were also associated with heart failure development and re-hospitalization at both 1 year ( P = .029, P = .009, respectively) and 2 years ( P = .019, P = .036, respectively). According to Cox multivariate analysis, left ventricular ejection fraction (LVEF) was an independent predictor of 2-year cardiovascular mortality ( P = .009), whereas galectin-3 was not ( P = .291). Although high galectin-3 levels were not independent predictors of long-term CV mortality in patients with acute STEMI who underwent primary PCI, it was associated with short-term and long-term development of adverse CV events, heart failure, and re-hospitalization.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Mehmet Akif Ersoy Thoracic and Cardiovascular Surgery Center, Training and Research Hospital, Istanbul, Turkey.
- Department of Biochemistry, Mehmet Akif Ersoy Thoracic and Cardiovascular Surgery Center, Training and Research Hospital, Istanbul, Turkey.
ORCID-Profile: Uğur Köktürk, Begüm Uygur, Nilgün Işıksaçan
Zitieren
APA
Köktürk, U., Püşüroğlu, H., Somuncu, M. U., Akgül, Ö., Uygur, B., Özyılmaz, S., Işıksaçan, N., Sürgit, Ö., & Yıldırım, A. (2023). Short and Long-Term Prognostic Significance of Galectin-3 in Patients with ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Angiology, 74(9), 889-896. https://doi.org/10.1177/00033197221149846
Vancouver
Köktürk U, Püşüroğlu H, Somuncu MU, Akgül Ö, Uygur B, Özyılmaz S, et al. Short and Long-Term Prognostic Significance of Galectin-3 in Patients with ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Angiology. 2023;74(9):889-896. doi:10.1177/00033197221149846
BibTeX
@article{Kktrk2023,
author = {Köktürk, Uğur and Püşüroğlu, Hamdi and Somuncu, Mustafa Umut and Akgül, Özgür and Uygur, Begüm and Özyılmaz, Sinem and Işıksaçan, Nilgün and Sürgit, Özgür and Yıldırım, Aydın},
title = {Short and Long-Term Prognostic Significance of Galectin-3 in Patients with ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention},
journal = {Angiology},
year = {2023},
volume = {74},
number = {9},
pages = {889--896},
doi = {10.1177/00033197221149846}
}
EUVIMED